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Breast cancer is the most commonly diagnosed cancer among
women in many Western populations (American Cancer Society,
2004), although in Asian countries this disease is comparatively
less frequent (Parkin et al, 1992). For example, breast cancer
incidence rates historically have been four to seven times higher
among women in the United States than those in China or Japan
(Kelsey and Horn-Ross, 1993), yet the underlying reasons for this
disparity are not entirely clear (Kelsey and Horn-Ross, 1993;
Ziegler et al, 1993). The geographic variation in risk does not
appear to be due to large genetic differences between ethnicities,
because breast cancer incidence rates among Asian-American
women shifts substantially toward those of white American women
within a few generations after migration (Chie et al, 1995; Stanford
et al, 1995; Wu et al, 1998).
These international variations in incidence rates coupled with
the results from migration studies suggest breast cancer risk is
influenced by environmental exposures, reproductive history, and
lifestyle choices, including diet (Kelsey and Horn-Ross, 1993;
Ziegler et al, 1993). Some researchers attribute the international
heterogeneity in risk to the higher consumption of soy products in
Asian countries (Ren et al, 2003). Since Americans and other
Western populations tend to consume less flavonoid-rich foods
compared to Asians and Asian-Americans (Dai et al, 2002), it is
possible that compounds in these products with known biologic
anti-cancer activity may decrease breast cancer risk and improve
survival after diagnosis.
Flavonoids, of which soy-based isoflavones are the most
intensely studied, lower endogenous hormone levels in pre- (Dai
et al, 2002; Ren et al, 2003) and post-menopausal women (Murkies
et al, 1995), and inhibit transcriptional factors involved in cancer
metastasis (Valachovicova et al, 2004; Slivova et al, 2005),
including vascular endothelial growth factor, which is strongly
associated with tumour angiogenesis (Masuda et al, 2002). These
findings provide support for a biologically plausible association
between dietary intake of flavonoids, particularly isoflavones, on
breast cancer risk and prognosis.
Unfortunately, the multiple investigations conducted to date
among human populations to evaluate a possible soy–breast
cancer link appear to be inconsistent and interpretation is not
straightforward. The meta-analysis presented by Wu et al in this
issue of BMJ was undertaken to obtain a summary effect estimate
of the association in epidemiologic studies. Their approach brings
clarity to the heated debate on this controversial issue.
One of the most important contributions of the meta-analysis
undertaken by Wu et al is the separation of the epidemiologic
studies conducted among Asian populations from those conducted
among Western populations. This simple stratified approach
elegantly demonstrates that a higher intake of isoflavones—about
20mg per day or more as compared with a lower intake of about
5mg per day—among Asian populations is associated with a
consistent 29% reduction in the risk of developing breast cancer.
Importantly, an inverse dose–response relation was evident;
modest intake of about 10mg per day of isoflavones was associated
with a modest 12% decrease in breast cancer risk. Further, the risk
reductions among Asian women were observed for both pre-and
postmenopausal breast cancer. Moreover, the effect appeared to be
stronger among those consuming soy during adolescence than
among those who had only consumed soy as an adult, although
research on early-life consumption patterns is sparse. In contrast,
isoflavone intake of about 0.8mg per day, which Wu et al reported
as the higher level of consumption among Western populations
(but which is obviously far below even the lower levels of intake for
Asian populations), was not associated with breast cancer risk. In
all, these exciting findings by Wu et al underscore the importance
of considering exposure dose and timing when evaluating the
effects of soy intake on breast cancer risk.
Other concerns have also contributed to the difficulty in
interpreting the numerous population studies on the soy–breast
cancer association, and again the thoughtful methodologic
approach of Wu et al sheds light on these issues. For example,
many of the investigations conducted to date have used the case–
control study design, which may yield biased effect estimates due
to possible differential recall of exposure based on the subjects’
case–control status. However, as shown by Wu et al, results
among Asian populations from both cohort and case–control
studies yielded nearly identical summary effect estimates. Further,
if recall bias was the underlying reason for the inverse association
noted in the meta-analysis presented by Wu et al, then the risk
reduction associated with isoflavone intake should have been
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Western populations, which was not the case. Thus, recall bias
does not appear to be the reason for the observed risk reductions
associated with soy intake among Asian populations.
An important issue that still remains unclear is whether any of
the biologically active anti-cancer flavonoid compounds influence
breast cancer risk among Western populations. Most previous
epidemiologic studies have been hampered by focusing solely on
intake of isoflavones, which are usually consumed by Westerners
through intake of soy-based products such as processed foods.
Challenges associated with assessing intake of isoflavones from
these types of products could perhaps be overcome by utilising a
biomarker of exposure, although single measures common to
epidemiologic studies are not easily interpreted. Instead, it may be
more productive to consider intake of a broader range of
flavonoids, many of which occur in foods more frequently
consumed by Western populations (such as tomatoes, green
peppers, berries, and citrus fruits (Fink et al, 2006)). These other
flavonoid classes can then be assessed using more conventional
nutritional epidemiology methods (Fink et al, 2006). Recent
studies conducted in Greece (Peterson et al, 2003), Italy (Bosetti
et al, 2005), and the United States (Fink et al, 2007b) using this
alternative approach consistently report a modest decrease in the
risk of breast cancer in relation to intake of flavones. Thus, further
exploration of the potential chemo-preventive effects of additional
flavonoid classes on breast cancer appears warranted.
The review by Wu et al also highlights other understudied
soy–breast cancer issues. In particular, the authors note that few
investigators have formally evaluated the effects of soy intake
on survival among women diagnosed with breast cancer.
For example, one study conducted among a cohort of women
with breast cancer in Shanghai (Boyapati et al, 2005) observed no
association between consumption of isoflavones at diagnosis and
subsequent mortality. In contrast, in a recent publication by our
own group (Fink et al, 2007a) a reduction in all-cause and breast
cancer-specific mortality was observed among a cohort of breast
cancer survivors in the United States, who reported consuming
higher levels of total flavonoids, and particularly flavones. To the
best of our knowledge, no other reports on this subject have been
published to date.
In sum, the meta-analysis by Wu et al notably demonstrate that
relatively high intake of 10–20mg per day of isoflavones, a
consumption level frequently found among Asian populations, is
inversely associated with a 10–30% reduction in risk of breast
cancer. Lower isoflavone intake of o1mg, a level more commonly
consumed by Western populations, does not appear to have any
beneficial effects on breast cancer risk. Additional research is
needed to assess whether soy consumption that begins during the
adult years is sufficient to decrease risk, or whether only intake
patterns that were initiated during childhood affect the subsequent
risk of developing breast cancer. In addition, clarification is
needed on whether intake of other flavonoid classes, particularly
those in foods such as fruits and vegetables more frequently
consumed by Western populations, are associated with breast
cancer risk reductions as has been shown for flavones in three
recently published studies. Lastly, whether consumption of
isoflavones or other flavonoid classes affects mortality among
breast cancer survivors has been evaluated in only two previous
reports, with conflicting results, and thus this issue also deserves to
be more extensively evaluated.
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